Compare Gilead Sciences, Inc. (GILD) vs Omnicom Group Inc. (OMC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Omnicom Group Inc. — how do they compare? Gilead Sciences, Inc. trades at $135.41 (market cap $168.35B), while Omnicom Group Inc. trades at $85.74 (market cap $23.58B). The key difference: Gilead Sciences, Inc. is far larger — about 7.1× Omnicom Group Inc.'s market cap, and Omnicom Group Inc. pays the higher dividend (3.72%). Which is the better fit depends on your goals.
| GILD | OMC | |
|---|---|---|
Market Cap | $168.35B | $23.58B |
Sector | Health | Media |
52-Week High | $155.80 | $86.22 |
52-Week Low | $110.56 | $67.27 |
Enterprise Value | $191.42B | $31.66B |
Dividend Yield | 2.42% | 3.72% |
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Omnicom Group Inc.
Omnicom is the world's second- largest ad holding company, based on annual revenue. The firm's services, which include traditional and digital advertising and public relations, are provided worldwide, with over 85% of its revenue coming from more developed regions such as North America and Europe.
Read more on OMC →
